#1 Clinical Trials Search in Europe

Human Immunoglobulin G1 Constant Region – Human Ectodysplasin-A1 Receptor-Binding Domain Fusion Protein

This article discusses a clinical trial exploring the use of ER004, a novel drug containing Human Immunoglobulin G1 Constant Region – Human Ectodysplasin-A1 Receptor-Binding Domain Fusion Protein, as a potential prenatal treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in male subjects. The trial aims to assess the drug’s efficacy and safety when administered through intra-amniotic injections during pregnancy.

Table of Contents

What is ER004?

ER004 is an innovative medication being developed to treat a rare genetic condition called X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). The scientific name for this drug is Human Immunoglobulin G1 Constant Region – Human Ectodysplasin-A1 Receptor-Binding Domain Fusion Protein. It’s a specially designed protein that combines parts of human antibodies with a protein that’s important for the development of certain body structures.[1]

What is X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)?

X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) is a rare genetic disorder that affects the development of certain body structures. People with XLHED typically have problems with their sweat glands, teeth, and hair. The “X-linked” part means that the condition is usually passed down from mothers to their sons. The “hypohidrotic” part refers to the reduced ability to sweat, which is a major feature of this condition.[1]

How ER004 Works

ER004 is designed to replace a protein that’s missing in people with XLHED. This missing protein is crucial for the proper development of sweat glands, teeth, and hair follicles. By giving ER004 to babies before they’re born (through a procedure called intra-amniotic administration), researchers hope to prevent or reduce the symptoms of XLHED.[1]

Clinical Trial Details

A clinical trial is currently underway to test ER004. Here are some key points about the trial:

  • It’s a Phase 2 trial, which means it’s testing both how well the treatment works and how safe it is.[1]
  • The main goal is to see if ER004 can improve the ability to sweat in baby boys with XLHED when they’re 6 months old.[1]
  • The treatment is given before birth, directly into the amniotic fluid surrounding the baby (intra-amniotic administration).[1]
  • The trial will also look at other effects of the treatment, such as tooth development and long-term safety, up to when the children are 5 years old.[1]

Eligibility Criteria

The trial has specific criteria for who can participate. Here are the main points:

  • For mothers:
    • Must be an adult woman who is pregnant (no later than 23 weeks and 6 days into the pregnancy)
    • Must be genetically confirmed as a carrier of the XLHED mutation
    • Should not have any active infections or medical conditions that increase the risk of preterm birth or other pregnancy complications[1]
  • For the unborn baby (fetus):
    • Must be male
    • Must have a confirmed diagnosis of XLHED
    • Should not have any other major health issues unrelated to XLHED[1]

Expected Benefits

If successful, ER004 could potentially improve several aspects of life for people with XLHED:

  • Increased ability to sweat, which is crucial for regulating body temperature
  • Better tooth development, potentially reducing dental problems
  • Possible improvements in other XLHED-related issues, such as skin problems and respiratory infections
  • Overall improvement in quality of life[1]

Safety Considerations

As with any new treatment, safety is a top priority. The trial will closely monitor both the mothers and the babies for any side effects or complications. Some key safety aspects include:

  • Monitoring the mothers during pregnancy and for one month after delivery
  • Tracking the health and development of the treated babies up to 5 years of age
  • Comparing the treated babies to untreated relatives with XLHED to better understand the effects of the treatment[1]

It’s important to note that while ER004 shows promise, it’s still in the testing phase. More research is needed to fully understand its effectiveness and safety. If you think you or a family member might be eligible for this trial, it’s best to discuss it with a healthcare provider who specializes in genetic disorders.

Aspect Details
Trial Type Phase 2, open-label, genotype-match controlled, multicenter clinical trial
Drug Name ER004 (Human Immunoglobulin G1 Constant Region – Human Ectodysplasin-A1 Receptor-Binding Domain Fusion Protein)
Condition Treated X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in male subjects
Administration Method Intra-amniotic injections during pregnancy
Primary Endpoint Mean sweat volume collected on both forearms after pilocarpine stimulation at 6 months of age
Secondary Endpoints Sweat pore density, dental development, salivation, XLHED-related hospitalizations, eczema assessment, safety and tolerability, quality of life
Follow-up Duration Up to 5 years for treated subjects, 1 month post-delivery for mothers
Key Inclusion Criteria Pregnant women (EDA mutation carriers), male fetuses with confirmed XLHED, untreated male relatives with same EDA mutation
Key Exclusion Criteria Maternal infections, pre-existing conditions increasing risk of preterm birth, fetal anomalies unrelated to XLHED

FAQ

  • What is X-linked Hypohidrotic Ectodermal Dysplasia (XLHED)? XLHED is a genetic condition that affects the development of ectodermal structures, including sweat glands, teeth, and hair. It primarily affects males and is characterized by reduced ability to sweat, which can lead to overheating and other health issues.
  • How is ER004 administered in this clinical trial? ER004 is administered through intra-amniotic injections, which means the drug is injected directly into the amniotic fluid surrounding the developing fetus during pregnancy.
  • What are the main objectives of this clinical trial? The main objectives are to assess the efficacy of ER004 on sweating ability, sweat pore density, and dentition in male XLHED subjects at 6 months of age, compared to untreated matched control subjects. The trial also aims to evaluate the drug's safety for both the treated subjects and their mothers.
  • Who is eligible to participate in this trial? Eligible participants include pregnant women who are confirmed carriers of an EDA mutation, male fetuses with a confirmed diagnosis of XLHED, and untreated male relatives with the same EDA mutation as the treated subject, aged between 6 months and 75 years.
  • How long will the subjects be monitored in this trial? The treated male subjects will be monitored for efficacy and safety up to 5 years of age, while their mothers will be monitored for safety up to 1 month after delivery.

Ongoing Clinical Trials on Human Immunoglobulin G1 Constant Region – Human Ectodysplasin-A1 Receptor-Binding Domain Fusion Protein

  • Study on ER004 for Treating Boys with X-linked Hypohidrotic Ectodermal Dysplasia (XLHED)

    Recruiting

    1 1
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • X-linked Hypohidrotic Ectodermal Dysplasia (XLHED): A genetic condition that affects the development of ectodermal structures such as sweat glands, teeth, and hair. It is inherited in an X-linked pattern, primarily affecting males.
  • Intra-amniotic: Refers to the administration of a substance directly into the amniotic fluid surrounding a developing fetus during pregnancy.
  • ER004: The investigational drug being studied in this trial, containing Human Immunoglobulin G1 Constant Region – Human Ectodysplasin-A1 Receptor-Binding Domain Fusion Protein.
  • EDA mutation: A genetic alteration in the EDA gene, which is responsible for the development of ectodermal structures and is associated with XLHED.
  • Pilocarpine-induced sweating: A method used to stimulate and measure sweat production by applying pilocarpine, a substance that promotes sweating.
  • Sweat pore density: The number of sweat pores per unit area of skin, typically measured per square centimeter.
  • Tooth bud: An early stage of tooth development, visible as a palpable structure in the alveolar ridge (the part of the jaw that holds the teeth).
  • Hypomorphic EDA mutation: A type of genetic mutation that results in a partial loss of gene function, as opposed to a complete loss (null mutation).
  • Eczema: A condition characterized by inflamed, itchy, and dry skin, which is often associated with XLHED.
  • Health-related quality of life: A measure of a person's perceived physical and mental health over time, used to assess the impact of a condition or treatment on overall well-being.

References

  1. http://clinicaltrials.eu/trial/study-on-er004-for-treating-boys-with-x-linked-hypohidrotic-ectodermal-dysplasia-xlhed/